Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]
In development
Reference number: GID-TA11544
Expected publication date:
In July 2024, NICE consulted on a scope for ID6441 semaglutide. Having reviewed the responses to consultation, we have reconsidered the approach we wish to take for this appraisal. A new consultation has been issued in Feb 2025 to propose to combine the appraisal of ID6441 with a review and update of existing guidance on the use of semaglutide for treating overweight and obesity (TA875). We also propose to update the terminated appraisal covering people aged 12 to 17 years (TA910).